

Dostarlimab

GARNET

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: EMA: As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.. FDA: Treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

Experimental Arm: Dostarlimab

Control Arm: Single arm



